摘要
纳米药物研发是主体参与技术创新实践的过程,研发技术主体与管理者主体是研发责任担当的主角。纳米药物研发的伦理责任主要表现为研发主体的创新责任和道义责任。由于纳米技术的滥用或许会导致新一轮的技术异化,对纳米药物的医学应用后果和社会效益进行科学审视和冷静反思是十分必要的。纳米药物的研发需要建立科学而可行的预警机制,建构明晰责任和惩戒制度以强化风险治理。而以技术美德论、新道义论和社会公益论思想强化对研发主体品性的塑造,有益于促进其责任的履行。纳米技术伦理问题的解决不仅是科学家和技术专家的事情,也是哲学家、伦理学家、管理者、法学家乃至政策制定者必须面对的课题。
The body of technology and the body of management are the main characters who take on the responsibility of the research and development for nanopharmaceuticals.The characteristics of the ethical responsibilities are the responsibility of innovation and the moral responsibility.The research and development for nanopharmaceuticals need to establish a scientific and feasible early warning mechanism,and construct clarity and disciplinary measures for responsibility in order to strengthen risk management system.Meanwhile the thoughts of the virtue of technology,new deontology and social welfare can strengthen the shape of virtues for the main bodies and are conductive to promoting the fulfillment of their responsibilities.
出处
《山东科技大学学报(社会科学版)》
2010年第5期15-20,共6页
Journal of Shandong University of Science and Technology(Social Sciences)
基金
辽宁省社会科学基金项目"纳米技术的伦理挑战及对策研究"(L08DZX021)
沈阳药科大学归国人员基金项目"医药伦理学前沿问题研究"(2009-3)
关键词
纳米药物
伦理责任
技术美德论
新道义论
社会公益论
nanopharmaceuticals
ethical responsibility
virtue of technology
new deontology
social welfare